1. Home
  2. ZYME vs SSII Comparison

ZYME vs SSII Comparison

Compare ZYME & SSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • SSII
  • Stock Information
  • Founded
  • ZYME 2003
  • SSII N/A
  • Country
  • ZYME United States
  • SSII India
  • Employees
  • ZYME N/A
  • SSII N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • SSII
  • Sector
  • ZYME Health Care
  • SSII
  • Exchange
  • ZYME Nasdaq
  • SSII Nasdaq
  • Market Cap
  • ZYME 1.2B
  • SSII 1.4B
  • IPO Year
  • ZYME 2017
  • SSII N/A
  • Fundamental
  • Price
  • ZYME $18.08
  • SSII $9.94
  • Analyst Decision
  • ZYME Strong Buy
  • SSII
  • Analyst Count
  • ZYME 8
  • SSII 0
  • Target Price
  • ZYME $24.00
  • SSII N/A
  • AVG Volume (30 Days)
  • ZYME 668.9K
  • SSII 135.5K
  • Earning Date
  • ZYME 11-06-2025
  • SSII 11-14-2025
  • Dividend Yield
  • ZYME N/A
  • SSII N/A
  • EPS Growth
  • ZYME N/A
  • SSII N/A
  • EPS
  • ZYME N/A
  • SSII N/A
  • Revenue
  • ZYME $122,867,000.00
  • SSII $27,623,624.00
  • Revenue This Year
  • ZYME $107.76
  • SSII N/A
  • Revenue Next Year
  • ZYME $2.35
  • SSII N/A
  • P/E Ratio
  • ZYME N/A
  • SSII N/A
  • Revenue Growth
  • ZYME 95.94
  • SSII 134.89
  • 52 Week Low
  • ZYME $9.03
  • SSII $2.48
  • 52 Week High
  • ZYME $19.50
  • SSII $22.42
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 65.50
  • SSII 71.74
  • Support Level
  • ZYME $18.21
  • SSII $8.50
  • Resistance Level
  • ZYME $19.10
  • SSII $10.00
  • Average True Range (ATR)
  • ZYME 0.69
  • SSII 0.95
  • MACD
  • ZYME 0.02
  • SSII 0.35
  • Stochastic Oscillator
  • ZYME 56.97
  • SSII 98.41

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About SSII SS Innovations International Inc.

SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.

Share on Social Networks: